ATE199899T1 - Spirocycloalkyl-substituierte azetidinone als hypocholesterolemische mittel - Google Patents

Spirocycloalkyl-substituierte azetidinone als hypocholesterolemische mittel

Info

Publication number
ATE199899T1
ATE199899T1 AT94907200T AT94907200T ATE199899T1 AT E199899 T1 ATE199899 T1 AT E199899T1 AT 94907200 T AT94907200 T AT 94907200T AT 94907200 T AT94907200 T AT 94907200T AT E199899 T1 ATE199899 T1 AT E199899T1
Authority
AT
Austria
Prior art keywords
optionally
alkenylene
sum
substituted
image
Prior art date
Application number
AT94907200T
Other languages
English (en)
Inventor
Sundeep Dugar
John W Clader
Duane A Burnett
Margaret E Browne
Harry R Davis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE199899T1 publication Critical patent/ATE199899T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT94907200T 1993-01-21 1994-01-19 Spirocycloalkyl-substituierte azetidinone als hypocholesterolemische mittel ATE199899T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US643993A 1993-01-21 1993-01-21
PCT/US1994/000421 WO1994017038A1 (en) 1993-01-21 1994-01-19 Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents

Publications (1)

Publication Number Publication Date
ATE199899T1 true ATE199899T1 (de) 2001-04-15

Family

ID=21720894

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94907200T ATE199899T1 (de) 1993-01-21 1994-01-19 Spirocycloalkyl-substituierte azetidinone als hypocholesterolemische mittel

Country Status (26)

Country Link
US (1) US5698548A (de)
EP (1) EP0681569B1 (de)
JP (1) JP2719445B2 (de)
KR (1) KR960700227A (de)
CN (1) CN1118163A (de)
AT (1) ATE199899T1 (de)
AU (1) AU683048B2 (de)
CA (1) CA2154257C (de)
CZ (1) CZ180195A3 (de)
DE (1) DE69426924T2 (de)
DK (1) DK0681569T3 (de)
EE (1) EE9400394A (de)
ES (1) ES2155849T3 (de)
FI (1) FI953497A0 (de)
GR (1) GR3035963T3 (de)
HU (1) HUT72592A (de)
IL (1) IL108368A0 (de)
LT (1) LT3595B (de)
NO (1) NO952884L (de)
NZ (1) NZ261714A (de)
PL (1) PL309978A1 (de)
PT (1) PT681569E (de)
SI (1) SI9400022A (de)
SK (1) SK91195A3 (de)
WO (1) WO1994017038A1 (de)
ZA (1) ZA94386B (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ331094A3 (en) * 1992-06-26 1995-09-13 Pfizer Steroidal glycosides and their use for treating hypercholesterolemia and atherosclerosis
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5648484A (en) * 1995-03-07 1997-07-15 Schering Corporation Catalytic enantioselective synthesis of a spriofused azetidinone
DE69621952T2 (de) 1995-10-31 2003-01-16 Schering Corp., Kenilworth Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AR023463A1 (es) 1999-04-16 2002-09-04 Schering Corp Uso de compuestos de azetidinona
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DE60106489T2 (de) * 2000-12-20 2005-10-13 Schering Corp. Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel
IL156488A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
EP1911462A3 (de) 2001-01-26 2011-11-30 Schering Corporation Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
PT1355644E (pt) * 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
IL157552A0 (en) 2001-03-28 2004-03-28 Schering Corp Enantioselective synthesis of azetidinone intermediate compounds
SI1429756T1 (sl) * 2001-09-21 2007-02-28 Schering Corp Zdravljenje ksantomov z azetidinonskimi derivati kot inhibitorji absorpcije sterola
EP1429756B1 (de) 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ATE485818T1 (de) * 2002-07-30 2010-11-15 Karykion Inc Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
AU2004233863B2 (en) 2003-04-24 2010-06-17 Incyte Holdings Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1918000A2 (de) 2003-11-05 2008-05-07 Schering Corporation Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング　コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
WO2005062824A2 (en) * 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
WO2005069900A2 (en) * 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
US20080045726A1 (en) * 2004-05-10 2008-02-21 Laboratorios Del Dr. Esteve, S.A. Spirolactams and Their Synthesis
EP1747197A1 (de) * 2004-05-10 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Regioselektive funktionalisierung und regioselektives schützen von spirolaktamen
EP1598336A1 (de) * 2004-05-20 2005-11-23 Laboratorios Del Dr. Esteve, S.A. Regioselektive Hydroxylierung, Funktionalisierung und Schutz von Spirolactamen
US7291728B2 (en) 2004-05-10 2007-11-06 Laboratories Del Dr. Esteve, S.A. Spirolactams and their synthesis
EP1676836A1 (de) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Regioselektive Hydroxylierung, Funktionalisierung und Schutz von Spirolactamen
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
US8361999B2 (en) 2005-04-04 2013-01-29 Pontificia Universidad Catolica De Chile Methods of treating cholesterol gallstone disease with ezetimibe
JP2008546784A (ja) * 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
CA2634940A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
BRPI0706623A2 (pt) 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
EP1986489A2 (de) * 2006-02-24 2008-11-05 Schering Corporation Npc1l1-orthologe
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
JP2010503676A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛、糖尿病および脂質代謝の障害の治療
CA2663500A1 (en) 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
CA2663503A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
CN101541805A (zh) * 2006-09-15 2009-09-23 先灵公司 用于治疗疼痛和脂代射紊乱的氮杂环丁烷和氮杂环丁酮衍生物
JP2010503673A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛および脂質代謝障害を処置する際に有用なアゼチジン誘導体およびアゼチドン誘導体
US20080070890A1 (en) * 2006-09-15 2008-03-20 Burnett Duane A Spirocyclic Azetidinone Compounds and Methods of Use Thereof
MX2009002921A (es) 2006-09-15 2009-04-01 Schering Corp Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
EP2548874A3 (de) 2007-06-28 2013-05-15 Intervet International B.V. Substituierte Piperazine als CB1-Antagonisten
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
PL2547679T3 (pl) 2010-03-19 2016-02-29 Pfizer Pochodne 2,3-dihydro-1H-inden-1-ylo-2,7-diazaspiro[3.5]nonanu i ich zastosowanie jako antagonistów lub odwrotnych agonistów receptora greliny
EP2844233B1 (de) 2012-05-01 2020-05-06 Althera Life Sciences, LLC Orale tablettenformulierung aus einer fixierten kombination aus rosuvastatin und ezetimib zur behandlung von hyperlipidämie und herz-kreislauf-erkrankungen
CN104496839B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
CN104496838B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
WO2020104930A1 (en) 2018-11-20 2020-05-28 Piramal Enterprises Limited An improved asymmetric synthesis of azaspiro compounds
JP7574206B2 (ja) 2019-03-20 2024-10-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ステロール調節エレメント結合転写因子１（ｓｒｅｂｆ１）阻害剤による上昇した脂質レベルの治療
WO2020191163A1 (en) 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
AU2022421224A1 (en) * 2021-12-22 2024-06-20 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
WO2025049558A1 (en) 2023-08-29 2025-03-06 Regeneron Pharmaceuticals, Inc. Treatment of liver disease or metabolic disorder with folliculin interacting protein 1 (fnip1) inhibitors and/or folliculin (flcn) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2048080C3 (de) * 1970-09-30 1979-11-29 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von N-substituierten 33-disubstituierten ß -Lactamen
US4692515A (en) * 1984-09-24 1987-09-08 Pennwalt Corporation Adamantane-spirolactams
IL89835A0 (en) 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5130425A (en) * 1990-10-12 1992-07-14 American Home Products Corporation Spiro-lactams and analogs thereof useful as aldose reductase inhibitors
TW223059B (de) * 1991-07-23 1994-05-01 Schering Corp

Also Published As

Publication number Publication date
DE69426924T2 (de) 2001-08-16
DK0681569T3 (da) 2001-04-23
HU9502194D0 (en) 1995-09-28
ZA94386B (en) 1994-07-19
IL108368A0 (en) 1994-04-12
LT3595B (en) 1995-12-27
AU683048B2 (en) 1997-10-30
EE9400394A (et) 1996-06-17
PT681569E (pt) 2001-06-29
US5698548A (en) 1997-12-16
CZ180195A3 (en) 1996-01-17
ES2155849T3 (es) 2001-06-01
PL309978A1 (en) 1995-11-13
GR3035963T3 (en) 2001-08-31
SK91195A3 (en) 1995-12-06
NZ261714A (en) 1997-02-24
KR960700227A (ko) 1996-01-19
DE69426924D1 (de) 2001-04-26
SI9400022A (en) 1995-02-28
CA2154257A1 (en) 1994-08-04
EP0681569B1 (de) 2001-03-21
NO952884L (no) 1995-09-20
HUT72592A (en) 1996-05-28
CA2154257C (en) 1999-05-25
FI953497A7 (fi) 1995-07-20
CN1118163A (zh) 1996-03-06
JP2719445B2 (ja) 1998-02-25
JPH08501110A (ja) 1996-02-06
NO952884D0 (no) 1995-07-20
LTIP1764A (en) 1995-02-27
WO1994017038A1 (en) 1994-08-04
AU6087294A (en) 1994-08-15
EP0681569A1 (de) 1995-11-15
FI953497A0 (fi) 1995-07-20

Similar Documents

Publication Publication Date Title
DE69426924D1 (de) Spirocycloalkyl-substituierte azetidinone als hypocholesterolemische mittel
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
BR0009651A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
CA2430692A1 (en) Geldanamycin derivative and use of same to treat cancer
MY115662A (en) Novel compounds with analgesic effect
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
IL150258A0 (en) Cascade polymer complexes
NO950275L (no) Kombinasjonsbehandling for osteoporose
CA2292359A1 (en) Novel azalides and methods of making same
AU6484199A (en) Carbamate and carbazate ketolide antibiotics
RU94037246A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща
RU94045277A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования расстройств цнс у женщин в постменопаузе
RU94045280A (ru) Средство для ингибирования патологических состояний молочных желез
DK0570294T3 (da) 2-formylpyridinthiosemicarbazonderivater, deres fremstilling og deres anvendelse som antitumormiddel
CA2094806A1 (en) Aminosulfonyl urea acat inhibitors
TW200420567A (en) Quinazoline derivatives
EP0273266A3 (de) Silikonderivat von Menthol als Medikament
IE832680L (en) Nitrosourea derivatives.
HUP9802736A2 (hu) 1,4-Dihidropiridin-származékok alkalmazása artériafal ateroszklerózisos degradálódásának megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
IL112110A0 (en) Octahydro-1h-isoindoles and pharmaceutical compositions containing them
RU94044323A (ru) Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления
AU3409795A (en) Methods for bone healing and fracture repair

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee